AzTrials
AzTrials

Refractory Acute Myeloid LeukemiaPhase 1NCT06017258

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

A Phase 1 study testing CD371-specific/YSNVz/I-18 CAR T cells in people with Refractory Acute Myeloid Leukemia and Relapsed Acute Myeloid Leukemia, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants. Read more about this study

Who is it for?
Ages 1 year and older
What is being tested?
CD371-specific/YSNVz/I-18 CAR T cells
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
7 sitesUnited States
Study dates
1 Sep 2023to 17 Dec 2027
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Subject Inclusion: Collection of T cells (Part A)
  • History of CD371+ AML
  • Any disease status is eligible for collection
  • Expression of CD371 at any level on AML blasts (any method of detection including IHC and/or flow cytometry)
  • Age/Weight
  • Pediatrics: ≥ 1 year and ≥ 10kg for collection for dose levels, 1, 2, and -1
Show all 46Show fewer
  • ≥ 12 years and ≥ 40 kg for collection for dose level 1A.
  • Adults: no limit on age/weight for collection for dose levels 1, 2, and -1.
  • ≥ 40 kg for collection for dose level 1A.
  • Patients with history of allo-HCT are eligible for collection if:
  • ≥ 100 days post-transplant however, as noted in Section 6.1.2, patients must be ≥180 days post-transplant to be eligible for treatment
  • no evidence of active GVHD
  • off any immunosuppressive agents for 30 days prior to collection (physiologic dose of corticosteroids is acceptable)
  • Subject Inclusion: Treatment with CD371-specific/YSNVz/IL-18 CAR T cells (Part B)
  • Relapsed/Refractory CD371+ AML (meeting criteria defined below) for primary refractory AML, late first relapse, and/or advanced disease:
  • o Primary refractory AML: Patients are eligible from disease perspective in the event of failure to achieve a CR, CRh or CRi after one or more of the following regimens:
  • Two or more courses of standard intensive induction chemotherapy (e.g., cytarabine and daunorubicin given as "7+3," MEC, HiDAC, FLAG+idarubicin, etc.);
  • Two or more cycles of venetoclax in combination with one of the following (azacitidine OR decitabine OR low-dose cytarabine), with or without other agents;
  • Six or more cycles of azacitidine monotherapy OR four or more courses of decitabine monotherapy
  • Early first relapse: Patients are eligible from disease perspective in the event of first morphologic relapse or new extramedullary disease less than 12 months after previously having achieved CR, CRh, or CRi following AML-directed therapy
  • Late first relapse: Patients with first morphologic relapse or new extramedullary disease ≥12 months after previously having achieved CR, CRh, or CRi following AML-directed therapy may respond to intensive re-induction using the initial induction regimen and not eligible from a disease perspective unless the treating investigator feels the patient is unlikely to benefit from repeating the initial induction regimen (for example, relapse occurring 12 months into CR on continuous azacitidine/venetoclax therapy), in which case the rationale for considering enrollment must be clearly documented and risks, benefits, and alternatives discussed with the patient.
  • Advanced disease: Patients are eligible from disease perspective in the event of relapsed AML refractory to reinduction therapy, relapse following alloHCT, or second or later relapse.
  • Disease eligibility considerations for all patients: Patients with relapsed or refractory AML with susceptible mutations for which there is an FDA approved therapy (for example, IDH1 mutation, ivosidenib; IDH2 mutation, enasidenib; FLT3-ITD/TKD, gilteritinib) are not eligible from a disease perspective unless they meet one or more of the below criteria:
  • Failure to achieve CR, CRh, or CRi following therapy with one or more targeted therapies for relapsed or refractory AML directed to the actionable mutation(s);
  • Intolerance of one or more targeted therapies for relapsed or refractory AML directed to the actionable mutation(s);
  • Treating investigator feels the patient would be unlikely to benefit from FDA-approved targeted therapy based on disease characteristics, in which case the rationale for considering enrollment must be clearly documented and risks, benefits, and alternatives discussed with the patient Age: any age is eligible for treatment if eligible for collection
  • o The first 3 patients in the first dose cohort must be ≥ 16 years of age, while the first 2 patients in subsequent cohorts must be ≥ 16 years of age (see Section 10.4) . Nopatient enrolled to dose level 1A shall be <12 years of age (and first 2 patients must be ≥ 16 years of age).
  • Adequate performance status:
  • Age ≥ 16 years: ECOG ≤ 1 or Karnosfsky ≥ 60
  • Age < 16 years: Lansky ≥ 60
  • Patients with history of allo-HCT are eligible for treatment if:
  • ≥ 180 days post-transplant
  • no evidence of active GVHD
  • off any systemic immunosuppressive agents for 30 days prior to treatment (physiologic dose of corticosteroids is acceptable)
  • Treating physician considers the patient to be a candidate for second alloHCT
  • Identification of a suitable donor/source for alloHCT as determined by the treating physician.
  • Adequate organ function is required, defined as follows:
  • Hepatic: Serum total bilirubin ≤ 1.5 mg/dL, unless benign congenital hyperbilirubinemia or unless thought to be disease related.
  • Hepatic: ALT and AST < 3 times the upper limit of normal unless thought to be disease-related.
  • Renal: serum creatinine < 2.0 mg/100 ml (> 18 years) or ≤ 2.5 x institutional upper limit of normal (ULN) for age
  • If serum creatinine is outside the normal range, then CrCl > 40 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.73m2) > 40% of predicted normal for age.
  • Normal GFR by Age Age: 1 week / Mean GFR +/-SD (mL/min/1.73 m2): 40.6 + / - 14.8 Age: 2 - 8 weeks / Mean GFR +/-SD (mL/min/1.73 m2): 65.8 + / - 24.8 Age: > 8 weeks / Mean GFR +/-SD (mL/min/1.73 m2): 95.7 +/- 21.7 Age: 2 - 12 years / Mean GFR +/-SD (mL/min/1.73 m2): 133 +/- 27 Age: 13 - 21 years (males) / Mean GFR +/-SD (mL/min/1.73 m2): 140 +/- 30 Age: 13 - 21 years (females) / Mean GFR +/-SD (mL/min/1.73 m2): 126.0 + / - 22.0 Abbreviations: GFR, glomerular f filtration rate; SD, standard deviation
  • Greater than 2 years old: Normal GFR is 100 mL/min/1.73m2.
  • Infants: GFR must be corrected for body surface area.
  • Cardiac: LVEF ≥ 50% by MUGA or resting echocardiogram.
  • Pulmonary: Adequate pulmonary function as assessed by ≥ 92% oxygen saturation on room air by pulse oximetry

Who cannot join

  • Subject Exclusion: Collection of T cells (Part A)
  • Pregnant or lactating women; women of childbearing age, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception while receiving study treatment and for at least 12 months after all treatment is finished
  • Sexually active males, unless they are willing to use a condom during intercourse while receiving study treatment and for at least 12 months after all treatment is finished
  • Radiographically-detected or symptomatic CNS disease or CNS 3 disease (i.e., presence of ≥ 5/ul WBC in CSF). Subjects with adequately treated CNS leukemia are eligible.
  • Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject
  • Impaired cardiac function (LVEF < 50%) as assessed by ECHO or MUGA scan
Show all 34Show fewer
  • Patients with following cardiac conditions will be excluded:
  • New York Heart Association (NYHA) stage III or IV congestive heart failure
  • Myocardial infarction ≤ 6 months prior to enrollment
  • History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
  • Positive serologic test results for HIV
  • Acute or chronic HBV infection as assessed by serologic (HBVsAg) or PCR results, defined as HBVsAg+, HBVcAb+, HBV PCR+.
  • Acute or chronic HCV infection as assessed by serologic (HCV ab) or PCR results, defined as HCV Ab+ with reflex to positive HCV PCR
  • Patient/parent/LAR unable to give informed consent/
  • Subject Exclusion: Treatment with CD371-specific/YSNVz/IL-18 CAR T cells (Part B)
  • Bridging chemotherapy occurring < 1 week prior to administration of LDC
  • o Exception: hydroxyurea can be continued up to 72 hours prior to leukapheresis or 24 hours prior to LDC
  • Pregnant or lactating women
  • Radiographically-detected or symptomatic CNS disease or CNS 3 disease (i.e., presence of ≥ 5/ul WBC in CSF). Subjects with adequately treated CNS leukemia are eligible.
  • Isolated extramedullary disease
  • Lack of a suitable donor/source for allogeneic HSCT as determined by the treating physician.
  • Patients with prior alloHCT are allowed as long as alloHCT occurred ≥100 days prior to date of treatment with CD371-specific/YSNVz/IL-18 CAR T cells and as long as the patient is without ongoing requirement for systemic graft-versus-host therapy
  • Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject
  • Impaired cardiac function (LVEF < 50%) as assessed by ECHO or MUGA scan.
  • Patients with following cardiac conditions will be excluded:
  • New York Heart Association (NYHA) stage III or IV congestive heart failure
  • Myocardial infarction ≤ 6 months prior to enrollment
  • History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
  • Positive serologic test results for HIV.
  • Acute or chronic HBV infection as assessed by serologic (HBVsAg) or PCR results, defined as HBVsAg+, HBVcAb+, HBV PCR+.
  • Acute or chronic HCV infection as assessed by serologic (HCV ab) or PCR results, defined as HCV Ab+ with reflex to positive HCV PCR
  • Active second malignancy that requires systemic treatments, with the exception of malignancy treated with curative intent and without evidence of disease for > 2 years before screening
  • Patient/parent/LAR unable to give informed consent
  • Any other condition/issue which, in the opinion of the treating physician, would make the patient ineligible for the study; conditions that in the Principal Investigator's opinion might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.

Trial locations and contacts

7 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Mark Geyer, MD contact

646-608-3745

geyerm@mskcc.org

Jae Park, MD contact

646-608-3743

parkj6@mskcc.org

7 sites in 1 country

United States7 sites, 7 recruiting

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920

    Mark Geyer, MD, 646-608-3745

    Recruiting

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)

    Commack, New York, 11725

    Mark Geyer, MD, 646-608-3745

    Recruiting

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York, 10604

    Mark Geyer, MD, 646-608-3745

    Recruiting

  • Memorial Sloan Kettering Monmouth (Limited protocol activities)

    Middletown, New Jersey, 07748

    Mark Geyer, MD, 646-608-3745

    Recruiting

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey, 07645

    Mark Geyer, MD, 646-608-3745

    Recruiting

  • Memorial Sloan Kettering Cancer Center (All protocol activites)

    New York, New York, 10065

    Mark Geyer, MD, 646-608-3745

    Recruiting

  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)

    Rockville Centre, New York, 11553

    Mark Geyer, MD, 646-608-3745

    Recruiting

Other trials in United States

About this study

Official title: Phase I Trial of CLEc12a (CD371) Targeted ArmoRed Immune Effector Cells in Patients With Relapsed/Refractory Acute Myeloid Leukemia (CLEAR-AML)

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

Being tested
CD371-specific/YSNVz/I-18 CAR T cells
Keywords
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, ArmoRed, CLEAR-AML, CLEc12a, CD371, Memorial Sloan Kettering Cancer Center, 23-016
Medical subject headings
Leukemia, Myeloid, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CD371-specific/YSNVz/I-18 CAR T cellsBiological

    Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

Study groups in NCT06017258
Study groupRoleWhat they receive
Dose Level 1ExperimentalParticipants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Receives: Biological: CD371-specific/YSNVz/I-18 CAR T cells
Dose Level 2ExperimentalParticipants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Receives: Biological: CD371-specific/YSNVz/I-18 CAR T cells
Step-Down DoseExperimentalParticipants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Receives: Biological: CD371-specific/YSNVz/I-18 CAR T cells

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum Tolerated Dose (MTD) of CAR T cells

    Determine the Maximum Tolerated Dose/MTD of CAR T cells in participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

    Measured: up to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2023
  2. Study start1 Sep 2023
  3. Primary completion17 Dec 2027 (estimated)
  4. Study completion17 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06017258
Sponsor's protocol ID
23-016
Status last verified
Oct 2026
First submitted
24 Aug 2023
Last updated
6 Oct 2026
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Publications

  • Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, McAvoy D, Katsamakis Z, Lorenc R, Lewis AM, Gipson B, Cuibus MA, Girotra NN, Wu K, Smith N, Burns ER, Um JS, Yoo S, Masouleh BK, Galera P, Hosszu K, Chaudhari J, Wang X, Lin Q, Curran KJ, Park JH, Scheinberg DA, van den Brink MRM, Abdel-Wahab O, Brentjens RJ, Daniyan AF. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood. 2025 Dec 25;146(26):3163-3174. doi: 10.1182/blood.2025029532.

    PubMed 40864984

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing CD371-specific/YSNVz/I-18 CAR T cells in people with Refractory Acute Myeloid Leukemia and Relapsed Acute Myeloid Leukemia, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 46 inclusion and 34 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mark Geyer, MD (646-608-3745, geyerm@mskcc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Tolerated Dose (MTD) of CAR T cells (time frame: up to 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06017258, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in